Why is Zantac the Subject of a Class-Action Lawsuit?

Why is Zantac the Subject of a Class-Action Lawsuit?

Why is Zantac the Subject of a Class-Action Lawsuit?

If you suffer from acid reflux or even experience the occasional bout of indigestion, you may have noticed that the popular heartburn medication Zantac has disappeared from the shelves of CVS and Walmart stores across the country. What you may not know is that the FDA is investigating high levels of a toxic substance called NDMA, which is found in ranitidine, the active ingredient of Zantac. Current reports cite discoveries of up to 26,000 times more than the FDA approved levels of NDMA found in doses of Zantac.

NDMA is a carcinogenic contaminant that is proven to cause cancer in animals and is thought to cause cancer in humans with enough exposure. It’s no surprise, then, that Sanofi and Boehringer Ingelheim, the manufacturers of Zantac, are facing class-action lawsuits in federal court.

 

What Is a Class-Action Lawsuit?

A class action or representative lawsuit is a way for many individuals to band together as one party represented by a single member who pursues a lawsuit in their collective interest. This is usually practiced when many people are suffering similar injuries, losses, or damages due to an unsafe product or the wrongful actions of a company.

Generally, the plaintiffs will seek fair financial compensation to mitigate the negative impact the product or company has had on their lives.

What Are the Plaintiffs Against Zantac Claiming?

The plaintiffs in the Zantac lawsuits case are claiming that Sanofi and Boehringer Ingelheim knowingly sold products that have the potential to cause cancer and other health complications. NDMA, the naturally occurring substance in ranitidine, is unstable and can multiply over time. By not adhering to FDA regulations in the use of ranitidine, the makers of Zantac ran the risk of NDMA levels in their products increasing over time. These dangerously increasing levels make NDMA more likely to be absorbed into the body of anyone who might unwittingly take these over-the-counter tablets or the even stronger prescription-strength medication to soothe symptoms of indigestion and other gastrointestinal issues.

 

Many of the plaintiffs involved in the class action are long time users of Zantac who have been diagnosed with various types of cancer linked to NDMA exposure, including liver, bladder, stomach, kidney, and esophageal cancers.

Who Can Join the Zantac Class-Action Lawsuit?

Zantac has been a very prevalent heartburn medication since the 1980s and has been used by millions of people over the years who believed it to be safe.

If you have ever taken Zantac or a generic equivalent regularly for more than 6 months, and have since been diagnosed with cancer, you may be eligible to join a class-action lawsuit.

If successful, a settlement could cover medical expenses incurred in cancer treatments, income lost while ill or in rehabilitation, and additional compensation for pain, suffering, and any other losses related to your illness.

Many class-action lawsuits will be filed against Sanofi and Boehringer Ingelheim in the coming years for allegedly endangering consumer health in the name of profits. If you or a loved one have developed a cancerous disease following the use of a ranitidine-based product, it’s important to seek the compensation you deserve.

No Comments

Post A Comment